Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda puts money in rare disease firm

by Ann M. Thayer
June 13, 2016 | A version of this story appeared in Volume 94, Issue 24

Takeda Pharmaceutical is investing $15 million in cash and purchasing $25 million worth of stock in Ultragenyx Pharmaceutical. Within 12 months, the Japanese company will have the option to purchase $25 million more of the rare disease firm’s stock. Ultragenyx will get an exclusive license to develop a preclinical candidate from Takeda for a specific genetic disease. Under a five-year collaboration, Ultragenyx will have the option to license up to five more Takeda compounds.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.